1: Hypertension. 2008 Feb 7 [Epub ahead of print]Related Articles,
Links
Effects of Losartan in Women With Hypertension and Left Ventricular
Hypertrophy. Results From the Losartan Intervention For Endpoint
Reduction in Hypertension Study.

Os I, Franco V, Kjeldsen SE, Manhem K, Devereux RB, Gerdts E, Hille
DA, Lyle PA, Okin PM, Dahlöf B, Oparil S.

Department of Nephrology.

Hypertension is a risk factor for cardiovascular disease and outcomes
in women. These posthoc analyses from the Losartan Intervention For
Endpoint reduction in hypertension (LIFE) study evaluated losartan-
versus atenolol-based therapy on the primary composite end point of
cardiovascular death, stroke, and myocardial infarction and other end
points in 4963 women. Fewer events occurred in women versus men. Women
in the losartan group had significant reductions in the primary end
point (215 [18.2 per 1000 patient-years] versus 261 [22.5 per 1000
patient-years]; hazard ratio [HR]: 0.82 [95% CI: 0.68 to 0.98];
P=0.031), stroke (109 versus 154; HR: 0.71 [95% CI: 0.55 to 0.90];
P=0.005), total mortality (HR: 0.77 [95% CI: 0.63 to 0.95]; P=0.014),
and new-onset diabetes (HR: 0.75 [95% CI: 0.59 to 0.94]; P=0.015)
versus the atenolol group, with no between-treatment difference for
myocardial infarction (HR: 1.02 [95% CI: 0.74 to 1.39]; P=0.925),
cardiovascular mortality (HR: 0.86 [95% CI: 0.64 to 1.14]; P=0.282),
or hospitalization for heart failure (HR: 0.94 [95% CI: 0.68 to 1.28];
P=0.677). More women in the losartan group required hospitalization
for angina (HR: 1.70 [95% CI: 1.16 to 2.51]; P=0.007). Risk reductions
for the primary composite end point, stroke, total mortality, and new-
onset diabetes were significantly greater with losartan- versus
atenolol-based treatment in women with hypertension and left
ventricular hypertrophy in the LIFE study. The risk reductions for
losartan, along with the tests for the interaction of treatment and
gender, indicated that the treatment effect was consistent in men and
women for all of the end points tested, with the exception of
hospitalization for angina.

PMID: 18259029 [PubMed - as supplied by publisher]

Not really a surprise
Thanks Vince